Literature DB >> 30387807

Knockdown of long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 inhibits the proliferation and migration of bladder cancer cells by modulating the microRNA-34a/cyclin D1 axis.

Ye Liu1, Saiyue Gao2, Qingyan Du2, Qingsong Zhao3.   

Abstract

Long non‑coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) has been demonstrated to participate in the development and progression of some common cancer types, including bladder cancer (BC). However, the regulatory mechanism of MALAT1 underlying BC growth and metastasis remains to be fully elucidated. The present study revealed that MALAT1 was significantly upregulated in BC tissues and cell lines compared with the adjacent non‑tumour tissues and the normal urinary tract epithelial cell line SV‑HUC‑1, respectively. The expression levels of MALAT1 were higher in stage III‑IV BC tissues when compared with that in stage I‑II tissues. Furthermore, knockdown of MALAT1 significantly inhibited BC cell proliferation and migration by targeting microRNA (miR)‑34a. The expression levels of miR‑34a were significantly decreased in BC tissues and cell lines compared with that of adjacent non‑tumour tissues and SV‑HUC‑1 cells. In addition, the expression of miR‑34a was inversely correlated with the expression of MALAT1 in BC tissues. The present study revealed that cyclin D1 (CCND1) was identified as a target gene of miR‑34a, and its expression was negatively mediated by miR‑34a in BC cells. Notably, the upregulation of CCND1 impaired the effect of MALAT1 inhibition on BC cell proliferation and migration. In addition, the expression levels of CCND1 were significantly increased in BC tissues and cell lines. In conclusion, the present findings demonstrated that the knockdown of lncRNA MALAT1 inhibits the proliferation and migration of BC cells by modulating the miR‑34a/CCND1 axis, suggesting that the MALAT1/miR‑34a/CCND1 axis may be a potential therapeutic target for BC treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30387807     DOI: 10.3892/ijmm.2018.3959

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  5 in total

Review 1.  The comprehensive landscape of miR-34a in cancer research.

Authors:  Sijing Li; Xiaohui Wei; Jinyong He; Quanquan Cao; Danyu Du; Xiaoman Zhan; Yuqi Zeng; Shengtao Yuan; Li Sun
Journal:  Cancer Metastasis Rev       Date:  2021-05-06       Impact factor: 9.264

Review 2.  Emerging Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis.

Authors:  Chunyu Zhang; Jiao Hu; Huihuang Li; Hongzhi Ma; Belaydi Othmane; Wenbiao Ren; Zhenglin Yi; Dongxu Qiu; Zhenyu Ou; Jinbo Chen; Xiongbing Zu
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

3.  Silencing of long chain noncoding RNA paternally expressed gene (PEG10) inhibits the progression of neuroblastoma by regulating microRNA-449a (miR-449a)/ribosomal protein S2 (RPS2) axis.

Authors:  Jian Zhang; Wei Liu; Ping Ji; Yan Zhang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

4.  rAAV-based and intraprostatically delivered miR-34a therapeutics for efficient inhibition of prostate cancer progression.

Authors:  Jianzhong Ai; Jia Li; Qin Su; Hong Ma; Ran He; Qiang Wei; Hong Li; Guangping Gao
Journal:  Gene Ther       Date:  2021-07-06       Impact factor: 4.184

5.  Prognostic and clinicopathological significance of long noncoding RNA MALAT-1 expression in patients with non-small cell lung cancer: A meta-analysis.

Authors:  Xiaoli Liu; Guichuan Huang; Jing Zhang; Longju Zhang; Zongan Liang
Journal:  PLoS One       Date:  2020-10-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.